Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by György Losonczy
Ceritinib in Second and Further Lines of Therapy in Advanced ALK Mutant Adenocarcinoma
Journal of Thoracic Disease
Pulmonary
Respiratory Medicine
Related publications
Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond
Expert Review of Anticancer Therapy
Oncology
Pharmacology
Proactive Management Strategies for Potential Gastrointestinal Adverse Reactions With Ceritinib in Patients With Advanced ALK-positive Non-Small-Cell Lung Cancer
Cancer Management and Research
Oncology
Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma
PLoS ONE
Multidisciplinary
Ceritinib Plus Nivolumab in Patients With Advanced ALK-rearranged Non-Small-Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Maximizing Response and Outcomes in Multimodality Therapy for Locally Advanced Esophageal Adenocarcinoma
Journal of Thoracic and Cardiovascular Surgery
Respiratory Medicine
Pulmonary
Cardiovascular Medicine
Surgery
Cardiology
P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.08-18 Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed by EMT
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Successful Rechallenge With Ceritinib After Leukocytoclastic Vasculitis During Ceritinib Treatment for Non-Small Cell Lung Cancer Harboring the EML4-ALK Fusion Protein
Oncotarget
Oncology
Concurrent Presence of ALK Rearrangement and MET Mutation in Lung Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
